FDA found Tianjin Bolang's otoscopes and rigid endoscopes failed device manufacturing rules after a 2021 inspection and is detaining imports.
What happened
FDA inspected the Tianjin facility from March 22 to March 30, 2021. The investigator found the firm lacked required design controls, corrective and preventive action (CAPA) procedures, complaint handling, distribution controls, device master and history records, a quality system record, and adequate training. FDA also found no written medical device reporting (MDR) procedures for its Class II Rigid Nasopharyngoscope and said the firm's responses were not adequate.
What FDA found
The firm had no design control procedures or design activities for its private-label endoscopic devices, including the Class II Rigid Nasopharyngoscope.
21 CFR 820.30(a)The firm had no corrective and preventive action procedures and did not collect quality data that could require such action.
21 CFR 820.100(a)The firm had no complaint handling procedures or complaint records and no written agreement requiring its sole U.S. distributor to send complaints for review.
21 CFR 820.198(a)The firm had no procedures to control distribution of finished devices and ensure only approved devices were released.
21 CFR 820.160The firm did not maintain device master records or device history records for its private-label endoscopic devices.
21 CFR 820.181; 21 CFR 820.184The firm had no written medical device reporting procedures, including how to submit reports electronically.
21 CFR 803.17
What FDA wants
FDA asks the firm to respond in writing within 15 business days with the specific steps taken to correct the violations, documentation of corrections and corrective actions, and a timetable for any work not yet complete. FDA also asks for English translations of documents not in English.
Who should pay attention
- U.S. distributors and importers of Tianjin Bolang endoscopes
- private-label brands that source these devices
- quality managers at medical device contract manufacturers
This is a summary. Read the original letter on fda.gov.